• Entrada Therapeutics director Bernhardt G. Zeiher reported an indirect purchase of 5,000 common shares.
• The shares were bought at a weighted-average price of $5.86.
• Indirect holdings following the transaction totaled 5,000 shares, held through the Bernhardt G Zeiher and Paula B Zeiher Revocable Living Trust Agreement.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Entrada Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001689375-26-000030), on May 21, 2026, and is solely responsible for the information contained therein.